Contraindications and medication recommendations for special populations when using Datopotamab

Datopotamab Deruxtecan, as an antibody drug conjugate targeting TROP-2, has some clear contraindications during its treatment. First of all, it is prohibited to be used by patients with severe allergic reactions to the ingredients of the drug or the excipients in its preparations. In addition, pregnant and lactating women should avoid using it due to the lack of sufficient safety data to prevent potential risks to the fetus or infant. For patients with active infections, such as severe bacterial, viral or fungal infections, it is recommended that medication be considered after the infection is controlled to reduce the risk of worsening of the infection during treatment.

Patients with abnormal liver and renal function should be treated with special caution when using dabrotuzumab. Because the metabolism and elimination of this drug are partially dependent on liver and kidney function, patients with severe hepatic impairment (e.g., Child-Pugh C grade) or severe renal impairment may be at risk for drug accumulation and increased toxicity. At present, there is insufficient clinical data for this type of patients, and individualized dosage adjustment and close monitoring should be carried out under the guidance of a professional doctor.

Elderly patients are usually accompanied by a variety of underlying diseases and reduced physiological functions. When using dedabrotuzumab, their overall health status and tolerance need to be comprehensively assessed. Elderly patients have weaker immune functions and are more susceptible to hematological toxicity and infection risks. Monitoring and supportive treatment should be strengthened. In addition, patients with chronic diseases such as cardiopulmonary disease and diabetes should pay special attention to possible complications when taking medication and adjust treatment plans in a timely manner to ensure safety.

There are insufficient safety and efficacy studies in children and adolescent patients and use is not recommended. During treatment, all patients need to undergo regular blood routine, liver and kidney function and lung imaging examinations to detect potential side effects in a timely manner. Women of childbearing age should take effective contraceptive measures to avoid pregnancy. Once serious adverse reactions occur during treatment, the medication should be suspended immediately, and the dose should be adjusted or treatment terminated if necessary to ensure patient safety.

In short, reasonable identification of contraindications and characteristics of special groups and individualized adjustment of medication regimens are the keys to the safe and effective application of dedabrotomab. Patients should receive standardized treatment under the guidance of a professional medical team to maximize drug efficacy and ensure drug safety.

Reference materials:https://www.fda.gov/drugs/